TD Asset Management Inc Cuts Stake in Lantheus Holdings, Inc. $LNTH

TD Asset Management Inc reduced its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 7.3% during the 2nd quarter, HoldingsChannel reports. The fund owned 632,592 shares of the medical equipment provider’s stock after selling 50,022 shares during the period. TD Asset Management Inc’s holdings in Lantheus were worth $51,784,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the stock. State of Michigan Retirement System lifted its position in shares of Lantheus by 0.6% during the first quarter. State of Michigan Retirement System now owns 16,600 shares of the medical equipment provider’s stock worth $1,620,000 after purchasing an additional 100 shares in the last quarter. Signaturefd LLC lifted its position in shares of Lantheus by 36.5% during the first quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider’s stock worth $42,000 after purchasing an additional 116 shares in the last quarter. Intrust Bank NA lifted its position in shares of Lantheus by 2.9% during the first quarter. Intrust Bank NA now owns 4,417 shares of the medical equipment provider’s stock worth $431,000 after purchasing an additional 125 shares in the last quarter. Focus Financial Network Inc. lifted its position in shares of Lantheus by 4.0% during the second quarter. Focus Financial Network Inc. now owns 3,576 shares of the medical equipment provider’s stock worth $293,000 after purchasing an additional 136 shares in the last quarter. Finally, Nisa Investment Advisors LLC lifted its position in shares of Lantheus by 2.1% during the first quarter. Nisa Investment Advisors LLC now owns 6,691 shares of the medical equipment provider’s stock worth $653,000 after purchasing an additional 139 shares in the last quarter. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Lantheus

In related news, insider Farallon Partners L. L C/Ca sold 3,365,000 shares of the business’s stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the completion of the sale, the insider owned 3,477,227 shares of the company’s stock, valued at $195,246,296.05. This represents a 49.18% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Rajiv A. Patel sold 3,365,000 shares of the business’s stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the sale, the insider directly owned 3,477,227 shares of the company’s stock, valued at approximately $195,246,296.05. This represents a 49.18% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 6,812,000 shares of company stock valued at $382,427,380. Insiders own 1.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on LNTH shares. Mizuho reduced their target price on shares of Lantheus from $120.00 to $70.00 and set an “outperform” rating on the stock in a research report on Thursday, August 7th. William Blair reiterated a “market perform” rating on shares of Lantheus in a research note on Wednesday, July 16th. The Goldman Sachs Group set a $77.00 target price on Lantheus and gave the company a “neutral” rating in a research note on Wednesday, October 8th. B. Riley reduced their target price on Lantheus from $109.00 to $84.00 and set a “buy” rating for the company in a research note on Tuesday, September 16th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Lantheus in a research note on Wednesday, October 8th. Four analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, Lantheus currently has a consensus rating of “Moderate Buy” and a consensus target price of $74.50.

Lantheus Trading Up 2.6%

Shares of NASDAQ LNTH opened at $56.52 on Thursday. The stock’s 50 day moving average price is $53.91 and its two-hundred day moving average price is $73.87. Lantheus Holdings, Inc. has a 52-week low of $47.25 and a 52-week high of $118.21. The stock has a market capitalization of $3.84 billion, a P/E ratio of 15.03 and a beta of 0.09. The company has a quick ratio of 4.07, a current ratio of 4.29 and a debt-to-equity ratio of 0.49.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Tuesday, May 17th. The medical equipment provider reported $0.05 earnings per share for the quarter. Lantheus had a net margin of 17.82% and a return on equity of 34.06%. The business had revenue of $92.51 million during the quarter. On average, analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.